• Onset: ~30-60 min to perceptible relaxation; Tmax ~1-2 hr (food delays Tmax modestly but doesn't change AUC meaningfully). Take ~30 min before bed.
• Peak: ~1-3 hours after dose. The feel is "reduced wakefulness drive," not sedation. Most users describe it as: thoughts slow down, not in a fog way but in a "I don't feel the need to keep doing things" way. Not a knock-out drug.
• Duration: Effective sleep window ~8 hours (matches half-life); wears off gradually overnight rather than abruptly.
• Morning: Generally clean at 25 mg; mild grogginess possible at 50 mg in the first week, fading with adaptation. Clinical trials and the 2025 Sleep Medicine paper show next-morning alertness improved vs placebo on average — but individual variability exists. The Drugs.com 43% negative cluster includes some grogginess complaints at 50 mg.
• Sleep maintenance: Strongest signal. Users report fewer middle-of-night awakenings — this matches the WASO phase-3 data (the strongest effect size).
• Sleep onset: Real but smaller than maintenance effect. Users with primary sleep-onset insomnia (vs maintenance) get less out of daridorexant relative to lemborexant.
• Dreams: Vivid dreams in some users — REM is preserved, possibly normalized. Distinguishing feature vs Z-drugs (which suppress REM and produce dreamless sleep).
• No "drugged" feeling: This is the big subjective separator from benzos/Z-drugs. Many users specifically choose daridorexant because they don't like the "not myself" feeling of zolpidem. The flip side is some users miss the forced sedation when their insomnia is severe.
• Discontinuation: No rebound insomnia, no withdrawal, no anxiety surge. Consistent across the 12-month extension data and user reports.

Honest variability: ~10-20% of users get minimal effect — likely the population whose insomnia is not orexin-driven (psychiatric, circadian, environmental, or sleep apnea-driven). Pharmacogenomics around CYP3A4 also matters (see below). Body habitus may matter — heavier users may need 50 mg over 25 mg.

• Tolerance buildup: None demonstrated through 12 months of nightly use (phase 3 + extension data). This is one of daridorexant's killer features vs Z-drugs.
• Recommended cycle: Cycling not required. Can be used PRN or nightly. PRN is preferred for Dylan-archetype users not chasing chronic insomnia.
• Reset protocol if needed: Not applicable — no tolerance to reset. If efficacy seems to fade, look at lifestyle/stack/comorbidity confounders before assuming tachyphylaxis.

Synergistic with

• l-tryptophan: Tryptophan feeds the melatonin pathway (substrate-side), daridorexant lowers wake drive (receptor-side). They work on different mechanisms with non-overlapping side effects. Tryptophan first, daridorexant if tryptophan alone is insufficient. Layered approach is the rational sleep stack.
• Magnesium glycinate (already V4): NMDA modulation + glycinergic relaxation. Mechanistically independent. Safe stack.
• Apigenin (already V4): GABA-A PAM at low doses. Theoretically additive but in practice neither produces strong sedation alone — combining is fine.
• L-theanine (already V4): GABA modulation + glutamate downregulation. Compatible.

Avoid stacking with

• Alcohol: Phase 1 study (PMID 33205362) shows additive PD impairment (saccadic velocity, body sway, alertness). FDA labeling says don't combine. For Dylan zero-alcohol baseline, irrelevant — flag for awareness.
• Strong CYP3A4 inhibitors (clarithromycin, ketoconazole, itraconazole, ritonavir, nefazodone, grapefruit juice in large quantities): AVOID — daridorexant exposure can rise 4-5×. Label says concomitant use not recommended.
• Moderate CYP3A4 inhibitors (diltiazem, erythromycin, fluconazole, fluvoxamine, verapamil, ciprofloxacin): Maximum 25 mg dose. Don't titrate to 50 mg.
• Strong CYP3A4 inducers (carbamazepine, phenytoin, rifampin, St. John's wort, efavirenz, apalutamide, enzalutamide): efavirenz alone reduced AUC by 61%. Daridorexant becomes ineffective with strong inducers — don't combine.
• Other CNS depressants (benzos, Z-drugs, opioids, gabapentinoids, phenibut, GHB): additive sedation and respiratory risk. Don't double-stack hypnotics.
• Bromantane (in V5 plan): not a hard contraindication but conceptually contradictory the same evening — bromantane upregulates dopamine synthesis (wake-supportive), daridorexant blocks orexin (sleep-supportive). If bromantane is being added in V5, take bromantane in the AM only and dose daridorexant at night with no overlap concern.
• Modafinil same calendar day: pharmacokinetically fine (modafinil is mostly cleared by CYP3A4 induction effects but doesn't significantly inhibit), but functionally redundant if daridorexant timing lets modafinil's R-enantiomer overlap into bedtime. The fix is modafinil dose timing (no later than 11 AM), not daridorexant dose adjustment.
• Selank same evening: mechanistically theta-rhythm modulation; shouldn't dangerous-stack but probably blunts daridorexant's sleep-permitting effect because Selank is mildly nootropic-alerting. Avoid combo.

Neutral / safe co-administration

• Citalopram — formal interaction study: no PK or PD interaction (J Psychopharmacology 2021). Generalizes loosely to other SSRIs but not formally tested.
• DHA / fish oil, NAC, citicoline, PS, curcumin, rhodiola, D3+K2, vitamin C, beta-alanine, creatine — no documented interactions, all V4 stack components are safe co-admin.
• Caffeine — not a hard interaction but functionally counterproductive in the 6-8 hr window before daridorexant dosing. Dylan's caffeine cutoff should be ~10 hours pre-bed regardless.

Daridorexant is a CYP3A4 substrate (primary metabolism, ~89% of clearance). The other 11% spreads across multiple minor enzymes (each <3%) — the system has no real backup, so CYP3A4 modulation hits exposure hard.

Daridorexant as a substrate (most important for stacking):

• Strong CYP3A4 inhibitors → AVOID. Exposures can rise 4-5×.
• Moderate inhibitors → max 25 mg. Includes commonly prescribed drugs (diltiazem, verapamil, fluconazole, ciprofloxacin, erythromycin, fluvoxamine).
• Strong inducers → likely subtherapeutic, switch class. Includes carbamazepine, phenytoin, rifampin, St. John's wort, efavirenz, apalutamide, enzalutamide.
• Grapefruit juice in routine quantities (>1 cup/day) — moderate CYP3A4 inhibitor in the gut. Avoid same-day.

Daridorexant as a perpetrator:

• At 25 mg: no effect on midazolam (sensitive CYP3A4 substrate) — clean.
• At 50 mg: midazolam AUC ↑ 42% (mild CYP3A4 inhibition). Practically meaningless for most stacks but worth knowing.
• No meaningful CYP induction.

Other relevant:

• Renal impairment: PK unchanged (hepatic clearance dominates). No dose adjustment needed — relevant for users with kidney issues (not Dylan).
• Hepatic impairment: Moderate impairment → ~1.6× exposure increase; severe impairment not studied. Avoid in moderate/severe hepatic impairment.
• Age >65: Slightly higher exposure but no formal dose adjustment required by labeling. Start at 25 mg in elderly.

• CYP3A4 polymorphisms are the dominant pharmacogenomic axis. CYP3A4 has high inter-individual expression variability driven more by environmental induction (diet, drugs) than by SNPs — but several known variants matter:
  • CYP3A4*22 (rs35599367, T allele): reduced enzyme activity → higher daridorexant exposure → lower dose may be needed. Frequency ~5-7% in Europeans, lower in Africans/Asians.
  • CYP3A5*3 (rs776746, G allele): the *3 allele is non-functional. Most Europeans (~90%) and Asians (~70%) are *3/*3 homozygotes (CYP3A5 non-expressors), shifting more metabolic load to CYP3A4. Dylan's Nordic/British ancestry → very likely CYP3A5 non-expressor; CYP3A4 status becomes the rate-limiting factor.
• 23andMe raw data check (June 2026): Look for CYP3A4*22 status. If Dylan is *22 carrier → start at 25 mg, do not titrate above without observation; consider this part of the bloodwork-gated stack calibration.
• No direct OX1/OX2 polymorphism implications are clinically established for daridorexant response. Some HCRTR2 SNPs have been studied in narcolepsy and depression contexts but no DORA-response pharmacogenomic data yet.
• CYP2C9, CYP2C19, CYP2D6: Minor contributors (<3% each) — Dylan's pending 23andMe data is more relevant for modafinil (CYP2D6 PM 7-10% in Caucasians) and bupropion (CYP2B6) than for daridorexant.

Practical sourcing for Dylan (US): Telehealth psychiatry or sleep visit → daridorexant 25 mg → use Idorsia QSavings card with commercial insurance for the first month copay, then reassess. If insurance denies, GoodRx at ~$150/mo is the fallback. No generic available pre-2032 — budget accordingly.

Baseline (before starting)

• Sleep diary 14 days minimum: sleep onset time, wake time, subjective TST, awakenings, morning alertness 0-10. Without 2 weeks of pre-trial diary, you cannot tell if the drug is doing anything.
• Optional actigraphy / wearable (Oura, Whoop, Apple Watch) — Dylan's project context includes Colmi R06 ring health platform; use it.
• Insomnia Severity Index (ISI) — 7-question validated tool. Pre-trial baseline.
• Epworth Sleepiness Scale — daytime sleepiness baseline.
• ALT/AST (liver baseline given CYP3A4 hepatic load) — already in June bloodwork plan.
• Sleep onset latency self-perception — note specifically "how long did it take to fall asleep" each night.

During use

• Sleep diary continued through trial period (4-6 weeks minimum to declare success/fail).
• ISI repeat at week 4 — clinically meaningful improvement is ≥6-point drop.
• Morning alertness 0-10 every morning — this is the most important biomarker for Dylan-archetype users. Brain-priority means morning-fog is a disqualifying side effect even if sleep itself improves.
• Cognitive task performance if available (n-back, reaction time tests) — track on day 7, 14, 28 vs baseline.
• Wearable sleep stage data (REM%, N3%, total sleep time, fragmentation) — multiple reasonable trackers will show this.
• Vivid dream / parasomnia log — note any sleep paralysis, hypnagogic hallucinations, dream intensity changes.

Post-cycle (if discontinuing)

• No rebound expected but track sleep diary for 2 weeks post-discontinuation to confirm. If rebound does occur → confound (stress, life event) is more likely than pharmacology.